Silvana Duran-Ortiz1, Stephen Bell2, John J Kopchick3. 1. Edison Biotechnology Institute, Heritage College of Osteopathic Medicine, Ohio University, Athens, OH 45701, United States; Department of Biological Sciences, College of Arts and Sciences, Heritage College of Osteopathic Medicine, Ohio University, Athens, OH 45701, United States; Molecular and Cellular Biology Program, Heritage College of Osteopathic Medicine, Ohio University, Athens, OH 45701, United States. Electronic address: sd504111@ohio.edu. 2. Edison Biotechnology Institute, Heritage College of Osteopathic Medicine, Ohio University, Athens, OH 45701, United States. Electronic address: bells1@ohio.edu. 3. Edison Biotechnology Institute, Heritage College of Osteopathic Medicine, Ohio University, Athens, OH 45701, United States; Molecular and Cellular Biology Program, Heritage College of Osteopathic Medicine, Ohio University, Athens, OH 45701, United States; Department of Biomedical Sciences, Heritage College of Osteopathic Medicine, Ohio University, Athens, OH 45701, United States. Electronic address: kopchick@ohio.edu.
Abstract
OBJECTIVE: Mice and humans with reduced growth hormone (GH) action before birth are conferred positive health- and life-span advantages. However, little work has been performed to study the effect of conditional disruption of GH action in adult life. With this as our objective, we sought to elucidate a reproducible protocol that allows generation of adult mice with a global disruption of the GH receptor (Ghr) gene, using the tamoxifen (TAM)-inducible Cre-lox system, driven by the ROSA26 enhancer/promoter. Here we report the optimum conditions for the gene disruption. DESIGN: Six month old mice, homozygous for the ROSA26-Cre and the Ghr-floxed gene, were injected, once daily for five days with four distinct TAM doses (from 0.08 to 0.32 mg of TAM/g of body weight). To evaluate the most effective TAM dose that leads to global disruption of the GHR, mRNA expression of the Ghr and insulin growth factor-1 (Igf1) genes were assessed in liver, adipose tissue, kidney, and skeletal and cardiac muscles of experimental and control mice. Additionally, serum GH and IGF-1 levels were evaluated one month after TAM injections in both, TAM-treated and TAM-untreated control mice. RESULTS: A dose of 0.25 mg of TAM/g of body weight was sufficient to significantly reduce the Ghr and Igf1 expression levels in the liver, fat, kidney, and skeletal and cardiac muscle of six-month old mice that are homozygous for the Ghr floxed gene and Cre recombinase. The reduction of the Ghr mRNA levels of the TAM-treated mice was variable between tissues, with liver and adipose tissue showing the lowest and skeletal and cardiac muscle the highest levels of Ghr gene expression when compared to control mice. Moreover, liver tissue showed the 'best' Ghr gene disruption, resulting in decreased total circulating IGF-1 levels while GH levels were increased versus control mice. CONCLUSION: The results show that in mice at six months of age, a total TAM dose of at least 0.25 mg of TAM/g of body weight is needed for a global downregulation of Ghr gene expression with a regimen of 100 μL intraperitoneal (ip) TAM injections, once daily for five consecutive days. Furthermore, we found that even though this system does not achieve an equivalent disruption of the Ghr between tissues, the circulating IGF-1 is >95% decreased. This work helped to create adult mice with a global GHR knockdown.
OBJECTIVE:Mice and humans with reduced growth hormone (GH) action before birth are conferred positive health- and life-span advantages. However, little work has been performed to study the effect of conditional disruption of GH action in adult life. With this as our objective, we sought to elucidate a reproducible protocol that allows generation of adult mice with a global disruption of the GH receptor (Ghr) gene, using the tamoxifen (TAM)-inducible Cre-lox system, driven by the ROSA26 enhancer/promoter. Here we report the optimum conditions for the gene disruption. DESIGN: Six month old mice, homozygous for the ROSA26-Cre and the Ghr-floxed gene, were injected, once daily for five days with four distinct TAM doses (from 0.08 to 0.32 mg of TAM/g of body weight). To evaluate the most effective TAM dose that leads to global disruption of the GHR, mRNA expression of the Ghr and insulin growth factor-1 (Igf1) genes were assessed in liver, adipose tissue, kidney, and skeletal and cardiac muscles of experimental and control mice. Additionally, serum GH and IGF-1 levels were evaluated one month after TAM injections in both, TAM-treated and TAM-untreated control mice. RESULTS: A dose of 0.25 mg of TAM/g of body weight was sufficient to significantly reduce the Ghr and Igf1 expression levels in the liver, fat, kidney, and skeletal and cardiac muscle of six-month old mice that are homozygous for the Ghr floxed gene and Cre recombinase. The reduction of the Ghr mRNA levels of the TAM-treated mice was variable between tissues, with liver and adipose tissue showing the lowest and skeletal and cardiac muscle the highest levels of Ghr gene expression when compared to control mice. Moreover, liver tissue showed the 'best' Ghr gene disruption, resulting in decreased total circulating IGF-1 levels while GH levels were increased versus control mice. CONCLUSION: The results show that in mice at six months of age, a total TAM dose of at least 0.25 mg of TAM/g of body weight is needed for a global downregulation of Ghr gene expression with a regimen of 100 μL intraperitoneal (ip) TAM injections, once daily for five consecutive days. Furthermore, we found that even though this system does not achieve an equivalent disruption of the Ghr between tissues, the circulating IGF-1 is >95% decreased. This work helped to create adult mice with a global GHR knockdown.
Authors: Christopher J Unterberger; Vilena I Maklakova; Michelle Lazar; Paige D Arneson; Sean J Mcilwain; Philippos K Tsourkas; Rong Hu; John J Kopchick; Steven M Swanson; Paul C Marker Journal: Endocrinology Date: 2022-05-01 Impact factor: 4.736
Authors: Silvana Duran-Ortiz; Kathryn L Corbin; Ishrat Jahan; Nicholas B Whitticar; Sarah E Morris; Ania N Bartholomew; Kira G Slepchenko; Hannah L West; Ibiagbani Mercy Max Harry; Edward O List; John J Kopchick; Craig S Nunemaker Journal: Am J Physiol Endocrinol Metab Date: 2021-05-03 Impact factor: 5.900
Authors: Silvana Duran-Ortiz; Edward O List; Yuji Ikeno; Jonathan Young; Reetobrata Basu; Stephen Bell; Todd McHugh; Kevin Funk; Samuel Mathes; Yanrong Qian; Prateek Kulkarni; Shoshana Yakar; Darlene E Berryman; John J Kopchick Journal: Aging Cell Date: 2021-11-22 Impact factor: 9.304